Insider Purchases: Inside the Buy
Tag: BiotechStocks
🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.
When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.
🧬 Annexon, Part 2: The $300,000 Guillain-Barré Cost Matrix and the Pipeline Fuse
Delve into the high-stakes financial and clinical reality of Guillain-Barré Syndrome (GBS)—a devastating neurological emergency carrying a brutal $300,000 cost of standard care. In Part 2 of our Annexon Biosciences (NASDAQ: ANNX) deep dive, we audit how their lead late-stage asset, Tanruprubart, targets C1q neuroinflammation at the source to completely upend healthcare economics, transform patient outcomes, and detonate an 11-day short squeeze trap.
1 comment
|
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?
This Wound Care Stock Doesn't Have to Hurt! 🩸🩼
CEO Joseph Capper is buying big. The company’s 9% full-year sales growth and 20%+ EBITDA margins suggest something’s brewing at this placental powerhouse. From PURION™ to profitability—this is wound care with a serious upside.